伊立替康(CPT-11)是结直肠癌及肺癌等实体肿瘤化疗的重要药物,但部分患者因发生严重腹泻及中性粒细胞缺乏等不良反应而导致化疗中止。在欧美及高加索人群中使用CPT-11发生3~4级不良反应概率约20%左右[1]。伊立替康的毒性与尿苷二磷酸葡糖醛转移酶1A1(UGT1A1)的多 Irinotecan (CPT-11) is an important drug for the chemotherapy of solid tumors such as colorectal cancer and lung cancer. However, some patients discontinued chemotherapy due to adverse reactions such as severe diarrhea and neutropenia. In Europe and the United States and Caucasians using CPT-11 occurred in 3-4 probability of adverse reactions about 20% [1]. Irinotecan toxicity and uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) and more